News NewAmsterdam says lead drug may have Alzheimer's role NewAmsterdam has said that an oral drug it is developing to lower cholesterol has shown early efficacy as a preventive therapy for Alzheimer's.
News Sanofi makes Alzheimer's play with Vigil takeover Sanofi bids to add a drug candidate for Alzheimer's disease to its neurology pipeline via the acquisition of US biotech Vigil Neuroscience.
News Alzheon Alzheimer's hopes dented by trial readout Alzheon has been left sifting through data from a failed Alzheimer's trial for crumbs of evidence that its oral therapy may have some efficacy.
News GSK makes fresh neuroscience foray with £2bn+ ABL deal Neuroscience isn't listed as one of the top R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting.
News Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug Buoyed by data from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's drug from its Brainshuttle programme.
News UK sets aside £2m for digitally-enhanced dementia tests The UK is providing £2m in funding to allow digital assessment to be added to a highly-anticipated trial of blood tests for diagnosing dementia.
News Most pharmas not ready for AI in customer engagement Pharma wants to use AI for digital engagement with healthcare professionals and patients, but most feel unprepared to forge ahead, says survey.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face